![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 05, 2017 12:00:05 AM
http://www.anipharmaceuticals.com/careers_positions.php#anchor66
Molecular Biologist with no work location... to work with contract manufacturer.... for generic acthar or something else?
Molecular Biologist
The Molecular Biologist position will work closely with contract manufacturing labs to create, execute and support the transfer and development of analytical methods for the quantitation of protein/peptide biologic drug substances and drug products.
Position Responsibilities: Provide technical expertise and experience to coordinate, design and carry out research projects involving the development of ELISA, potency and cell-based molecular biological analytical methods.
Collaborate exclusively with Research Scientists and Associates of several contract manufacturing labs on multiple projects, while taking personal responsibility for success of assigned tasks and projects.
Position Requirements: - Ph.D. in molecular or cellular biology, or biochemistry, with 3+ years of relevant post graduate experience, preferably in industry experience in ELISA development.
- Masters in molecular or cellular biology, or biochemistry with 10+ years of relevant experience.
- Proven expertise in the design and hands-on experience with conducting the development of ELISA assays.
- Experience with cell biology and/or molecular biology experiments is a must (e.g. qPCR, ELISA, Western blotting, SDS-PAGE, etc.)
- Ability to coordinate multiple projects in a fast paced environment.
- Demonstrated ability to perform in a team environment.
- Excellent communication skills
- Excellent organizational and follow-through skills
- Interpersonal skills
- Troubleshooting ability
- Experience with HPLC, bioinformatics and proteomics.
- Ability to plan, organize, implement, and product transfer projects, plans and objectives
- Demonstrated leadership skills
- Previous pharmaceutical industry experience
Recent ANIP News
- ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner • GlobeNewswire Inc. • 06/25/2024 11:00:02 AM
- ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences • GlobeNewswire Inc. • 06/24/2024 10:50:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 08:37:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:23:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:51:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:21:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:34:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:59:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 10:08:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:35:27 PM
- ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:03:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:02:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:58:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:54:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:45:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:06:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 10:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:21:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2024 08:57:32 PM
- ANI Pharmaceuticals Announces the Launch of Kionex® Suspension • GlobeNewswire Inc. • 05/20/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:50:06 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM